The FGF23 coreceptor αKlotho (αKL) is expressed as a membrane-bound protein (mKL) that forms heteromeric complexes with FGF receptors (FGFRs) to initiate intracellular signaling. It also circulates as an endoproteolytic cleavage product of mKL (cKL). Previously, a patient with increased plasma cKL as the result of a translocation [t(9;13)] in the αKLOTHO (KL) gene presented with rickets and a complex endocrine profile, including paradoxically elevated plasma FGF23, despite hypophosphatemia. The goal of this study was to test whether cKL regulates phosphate handling through control of FGF23 expression. To increase cKL levels, mice were treated with an adeno-associated virus producing cKL. The treated groups exhibited dose-dependent hypophosphatemia and hypocalcemia, with markedly elevated FGF23 (38 to 456 fold). The animals also manifested fractures, reduced bone mineral content, expanded growth plates, and severe osteomalacia, with highly increased bone Fgf23 mRNA (>150 fold). cKL activity in vitro was specific for interactions with FGF23 and was FGFR dependent. These results demonstrate that cKL potently stimulates FGF23 production in vivo, which phenocopies the KL translocation patient and metabolic bone syndromes associated with elevated FGF23. These findings have important implications for the regulation of αKL and FGF23 in disorders of phosphate handling and biomineralization.
Introduction
The bone-derived hormone FGF23 and its coreceptor αKlotho (αKL) are critical regulators of systemic phosphate metabolism. The αKL gene product is expressed as multiple species; the membrane-bound form (mKL) associates with FGF23 and FGF receptors (FGFRs) to signal through the MAPK cascade (1, 2) . Two soluble species have also been reported, an alternatively spliced secreted form (sKL) (exons 1-3 of the 5-exon KL gene) and an endoproteolytic cleavage product of mKL (cKL) (3) . Although sKL was identified as a potential αKL variant, only cKL protein was detectable in human and rodent plasma and cerebrospinal fluids (4) . The cKL form has been implicated in directly mediating renal phosphate handling through paracrine activity (5); however, whether endocrine effects of cKL occur remains unclear. This possibility is highlighted by findings in a patient with a translocation in the αKLOTHO (KL) gene (t9;13), who presented with elevated plasma cKL and a ricketic phenotype (6) . The biochemical and endocrine abnormalities were complex and included hypophosphatemia, hypocalcemia, inappropriately normal 1,25(OH) 2 vitamin D (1,25D), and severe hyperparathyroidism requiring surgical intervention. Of note, this patient also had sustained, highly elevated plasma FGF23 (>12 times the upper limit of normal), despite marked hypophosphatemia on or off calcitriol treatment (6) . The paradoxically elevated FGF23 in this patient, together with a clinical phenotype resembling that of patients with severe autosomal dominant hypophosphatemic rickets, X-linked hypophosphatemia, and tumor-induced osteomalacia (7) , is consistent with cKL functioning to direct the expression of FGF23. The goal of this study was to examine the ability of circulating cKL to act as an endocrine regulator of phosphate metabolism through controlling FGF23 production.
Fgf23 mRNA in the AAV-cKL-treated mice (Figure 2A ). The downstream targets, Egr1 and c-fos mRNAs, both known to be responsive to FGF23-αKL activity (8, 9) , were also upregulated in bone ( Figure 2B ). Kidneys had reduced mRNA expression of the type IIa sodium-phosphate cotransporter (Npt2a, also known as Slc34a1; Figure 2C ) and vitamin D 1α-hydroxylase (Cyp27b1; Figure 2D ), with elevated vitamin D 24-hydroxylase (Cyp24; Figure 2E ) mRNA. KL mRNA was not different between groups ( Figure 2F ). These effects are consistent with increased circulating Fgf23 and opposite to findings in animals made hypophosphatemic through low-phosphate diet (10) . The skeletal changes in the high-dose AAV-cKL group were dramatic, as micro-CT (μCT) revealed that distal and midshaft femora had significantly reduced bone mineral density (BMD) and bone mineral content (BMC), and lumbar vertebrae had reduced BMC and total area (Table 1) . Further, widened growth plates were detected in the distal femora and tibias ( Figure 2G ). Radiography revealed lower femoral radiodensity and spontaneous fractures ( Figure 2H ), which were accompanied by severe osteomalacia, as evaluated by histopathology ( Figure 2I ). Histomorphometry demonstrated that the amount of mineralized trabecular bone was lower in AAV-cKL animals, yet these mice had significant nonmineralized tissue, increasing the total amount of mineralized and nonmineralized tissue volume to 8-fold higher in the AAV-cKL-treated mice compared with that in control mice (P < 0.01; Supplemental Table 1 ; supplemental material available online with this article; doi:10.1172/JCI64986DS1).
Bioactivity of recombinant cKL. Enhanced cell viability through antiapoptotic effects is a known readout for cKL bioactivity (11) . NIH3T3 cells were treated with increasing concentrations of cKL and FGF23 either alone or in combination. Following serum withdrawal, the combination of FGF23 plus cKL markedly increased cell viability (EC 50 , 1 nM; Figure 3A ) at concentrations several orders of magnitude less than those required for either FGF23 or cKL alone (EC 50 , >5 μg/ml; Figure 3A ). The effects of cKL were specific to FGF23 since treatment with either FGF19 or 21, endocrine FGFs that interact with the β-Klotho coreceptor, did not prevent cell apoptosis ( Figure 3B ). A pan-FGFR inhibitor, but not its inactive isomer, dramatically decreased the cell survival effects of cKL and FGF23, supporting that the actions of cKL and FGF23 are FGFR mediated ( Figure 3C ). Further, following transfection of the FGFR-negative cell line L6 with FGFR1c, FGF23 plus cKL, but not FGF21 plus cKL, stimulated FGFR1 and ERK1/2 phosphorylation ( Figure 3D ).
These findings show that cKL-dependent stimulation of FGF23 production "overrides" low serum phosphate, a strong physiological suppressor of FGF23, and is consistent with the clinical profile of a described patient with KL translocation (6) . In this regard, mice exposed to cKL manifested hypophosphatemia (FigFigure 1 Biochemical and endocrine effects of AAV-cKL in vivo. (A) Mice treated with AAV-cKL (3 × 10 10 or 1 × 10 11 gc per mouse) developed dose-dependent hypophosphatemia by 2 weeks of treatment and (B) hypocalcemia by 4 to 8 weeks (n = 5-8 per group; P < 0.05 vs. AAV-LacZ or vehicle). *P ≤ 0.05 vs. vehicle; **P ≤ 0.001 vs. vehicle; # P ≤ 0.05 vs. LacZ; ## P ≤ 0.001 vs. LacZ. (C) cKL ELISA showed dose-dependent increases in serum cKL at 2 and 8 weeks of AAV-cKL expression, whereas vehicle and AAV-LacZ controls showed no increases above baseline concentrations (n = 5-8 per group; P < 0.05 vs. vehicle and AAV-LacZ). In the inset, the immunoblot shows expression of cKL in AAV-cKL mouse liver compared with that of vehicle control (Ctl). β-Actin was used to normalize gel loading. *P < 0.05; **P < 0.001 vs. vehicle and AAV-LacZ. (D) Serum intact FGF23 was markedly elevated in the AAV-cKL groups at 2 and 8 weeks (*P < 0.01; **P < 0.005). (E) PTH was also increased in the AAV-cKL groups (*P < 0.01). Values are shown as mean ± SEM. ure 1A) and hypocalcemia ( Figure 1B) , with highly elevated bone Fgf23 mRNA (Figure 2A ) and circulating protein ( Figure 1D) , with metabolic bone disease (Figure 2, G-I) . The cKL-treated animals also demonstrated hyperparathyroidism ( Figure 1E ) similar to that reported in the patient with KL translocation. Whether this effect was due to hypocalcemia ( Figure 1B ) from FGF23-dependent altered 1,25D metabolism or via direct effects of cKL on the parathyroid glands in which αKL is normally expressed remains to be determined. cKL has been implicated as a phosphaturic factor that functions by directly interacting with kidney Npt2a protein to inhibit phosphate reabsorption (5) . If the dominant effect of cKL was to induce hypophosphatemia independently of FGF23, following cKL delivery, the predicted endocrine response would be FGF23 suppression. In contrast, the present studies demonstrated that cKL caused robust increases in Fgf23 mRNA and protein despite the prevailing hypophosphatemia (Figures 1 and 2) . Additionally, the renal gene responses for regulators of phosphate and vitamin D metabolism were consistent with elevated FGF23 (Figure 2 , C-E) and are reciprocal to those caused by FGF23-independent hypophosphatemia. While potent, cKL is not the sole regulator of FGF23, as αKL-null mice have elevated FGF23, likely driven by 1,25D and/or a yet-identified mechanism for sensing hyperphosphatemia. The AAV-cKL-treated mice had severe osteomalacia (Figure 2) , consistent with the prevailing hypophosphate- Figure 1A) , as we detected an increase in total trabecular bone driven by an increase in nonmineralized tissue (Supplemental Table 1 ). The activity of cKL was selective for FGF23 (Figure 3) , which supports the concept of cKL potentially regulating FGF23 production through cKL-FGF23-FGFR interactions ( Figure 3) in bone, the primary source of this hormone. Consistent with these findings, patients with activating mutations in FGFR1c have elevated plasma FGF23 (12) , and reciprocally, suppression of FGFR activity inhibits FGF23 production (13) . Whether cKL interacts specifically with FGFR1c in vivo and whether this system could be modulated as a therapeutic target remain to be determined. In conclusion, these studies demonstrate that cKL is an important factor in regulating FGF23 production and significantly modify the current models of phosphate homeostasis, with implications for understanding the control of FGF23 expression during normal and disordered phosphate handling. 
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RNA isolation and qPCR
Femur and kidney RNA were harvested using TRIzol (Life Technologies) , and RNA samples were tested with primers specific for mouse Fgf23, Egr1, c-fos, Cyp27b1, Cyp24, Npt2a, and internal control β-actin as previously described (16) . The TaqMan One-Step RT-PCR Kit (Life Technologies) was used to perform qPCR, and data were collected using the 7500 Real-Time PCR system and software (Life Technologies) and analyzed using the 2 -ΔΔCT method.
Immunoblotting
Liver samples were homogenized in lysis buffer (Cell Signaling Technology) on ice using a rotor-stator homogenizer. Immunoblot analysis was performed similar to that previously described (8) , with 50 μg lysates per sample. Blots were acid stripped and reprobed with anti-actin-HRP (1:25,000; Sigma-Aldrich). L6-hFGFR1c cell lysates were blotted as described previously (15) and also probed with anti-phospho-ERK1/2 and anti-β-actin (Cell Signaling Technology).
Serum biochemistries
Calcium and Inorganic Phosphorous Reagent Kits (Roche) were used for serum measurements in a Hitachi analyzer (Roche Diagnostics). Serum FGF23 was tested using an "intact" FGF23 ELISA (Kainos Laboratories). Parathyroid hormone (PTH) was measured using a mouse-specific PTH ELISA (Immutopics International), and plasma cKL was quantified using a sandwich ELISA prepared with polyclonal antibodies recognizing the extracellular domain of mouse αKL (antibodies AF1819 and BAF1819; R&D Systems).
Statistics
Statistical analyses of the data were performed by 2-tailed Student's t test, and significance for all tests was set at P < 0.05.
Study approval
Animal studies were approved by the Indiana University Institutional Animal Care and Use Committee and the internal review board at Eli Lilly and Company and are in accord with NIH guidelines for humane treatment of laboratory animals.
